Should Investors Dismiss Friday's Selloff?
Last Friday, stock markets pulled back after tensions between Israel and Iran heightened caution among investors. The Dow Jones lost 1.79%, while the Nasdaq (QQQ) and S&P 500 (IVV) dropped.Not surprisingly, technology stocks declined, led by Nvidia (NVDA). Should investors dismiss the market’s mild selloff? The market rebounded, ever since the Liberation Day set fresh lows. It needed an excuse to pull back.Tech stocks have the most downside risks since valuations are excessive. Broadcom (AVGO), Analog Devices (ADI), Salesforce (CRM), and Adobe Systems (ADBE) are examples of high-flying firms to consider selling. Oracle (ORCL), by contrast, gained 7.68% on June 13 after posting strong results. The database supplier traded at new highs, giving Larry Ellison the title of the world’s second richest person. The company has a remaining performance obligation of $138 billion, up by $8 billion from the previous quarter.Oracle’s 41% RPO growth is impressive. Although investors missed out on the ORCL stock rally, they may continue to hold onto growth companies. Credo Technology (CRDO), for example, posted revenue growth of 179.7% Y/Y to $170.03 million in its first quarter. It is projecting customer base diversification. Three hyperscaler solutions contributed to more than 10% of its revenue. Credo has a strong market position. Its optical market is gaining traction. Expect the firm to win more contracts in the 800-gig transceiver markets.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


